- Home
- ACCS vs ACRV Comparison
ACCS vs ACRV Comparison
Compare ACCS & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCS
- ACRV
- Stock Information
- Founded
- ACCS 1988
- ACRV 2018
- Country
- ACCS United States
- ACRV United States
- Employees
- ACCS N/A
- ACRV N/A
- Industry
- ACCS Publishing
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ACCS Consumer Discretionary
- ACRV Health Care
- Exchange
- ACCS Nasdaq
- ACRV Nasdaq
- Market Cap
- ACCS 44.2M
- ACRV 40.4M
- IPO Year
- ACCS N/A
- ACRV 2022
- Fundamental
- Price
- ACCS $12.20
- ACRV $1.26
- Analyst Decision
- ACCS Strong Buy
- ACRV Buy
- Analyst Count
- ACCS 1
- ACRV 7
- Target Price
- ACCS $15.00
- ACRV $17.60
- AVG Volume (30 Days)
- ACCS 14.6K
- ACRV 287.7K
- Earning Date
- ACCS 08-11-2025
- ACRV 08-12-2025
- Dividend Yield
- ACCS N/A
- ACRV N/A
- EPS Growth
- ACCS N/A
- ACRV N/A
- EPS
- ACCS N/A
- ACRV N/A
- Revenue
- ACCS $22,961,000.00
- ACRV N/A
- Revenue This Year
- ACCS $3.05
- ACRV N/A
- Revenue Next Year
- ACCS $15.47
- ACRV $1,037.93
- P/E Ratio
- ACCS N/A
- ACRV N/A
- Revenue Growth
- ACCS 6.92
- ACRV N/A
- 52 Week Low
- ACCS $7.79
- ACRV $1.05
- 52 Week High
- ACCS $13.35
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- ACCS N/A
- ACRV 43.05
- Support Level
- ACCS N/A
- ACRV $1.34
- Resistance Level
- ACCS N/A
- ACRV $1.48
- Average True Range (ATR)
- ACCS 0.00
- ACRV 0.10
- MACD
- ACCS 0.00
- ACRV -0.01
- Stochastic Oscillator
- ACCS 0.00
- ACRV 17.24
About ACCS ACCESS Newswire Inc. Common Stock
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.